Article
Biochemistry & Molecular Biology
Julia Figl, Heike Koehler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann, Christian Menge
Summary: A more effective vaccine against tuberculosis is urgently needed. The recombinant vaccine VPM1002 has been found to be safer and more efficacious than the existing vaccine BCG in mice models. In this study, the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, were assessed in juvenile goats. The results showed that VPM1002 and NUOG induced anti-tuberculous immunity with a comparable safety profile to BCG.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Valdone Miseviciene, Gintare Liakaite, Elena Suciliene, Inga Ivaskeviciene
Summary: BCG-induced osteomyelitis is an extremely rare systemic adverse reaction in immunocompetent children after BCG vaccination, with correct diagnosis frequently missed. This article presented 4 clinical cases reported over a 10-year period in Lithuania, a high TB incidence country, and briefly reviewed the clinical, management, and treatment features of the disease.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2021)
Article
Pharmacology & Pharmacy
Leontine van Balveren, Eugene P. van Puijenbroek, Linda Davidson, Florence van Hunsel
Summary: Reactivation of BCG scar is observed after COVID-19 vaccination with mRNA and viral vector vaccines, characterized by erythema and pain within a few days. The exact mechanism remains unknown, but heat shock protein 65 may be involved.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Review
Immunology
Shruti Srivastava, Sajal Dey, Sangita Mukhopadhyay
Summary: Tuberculosis (TB) is a major cause of death, killing over 30,000 people per week and surpassing other infectious diseases like AIDS and malaria. TB treatment is affected by factors such as ineffective drugs, lack of advanced vaccines, misdiagnosis, improper treatment, and social stigma. Different vaccine strategies have been employed, including protein subunit vaccines, viral vector vaccines, whole-cell inactivation vaccines, and recombinant BCG vaccines. Currently, there are approximately 19 vaccine candidates in clinical trials. Advanced vaccines that generate heterologous immune responses are needed to enhance long-lasting immunity against both drug-sensitive and drug-resistant TB.
Article
Immunology
Frederik Schaltz-Buchholzer, Peter Aaby, Ivan Monteiro, Luis Camala, Simone Faurholt Simonsen, Hannah Nortoft Frankel, Kristina Lindberg Larsen, Christian N. Golding, Tobias R. Kollmann, Nelly Amenyogbe, Christine Stabell Benn, Morten Bjerregaard-Andersen
Summary: Providing BCG + OPV vaccination to neonates in the neonatal intensive care unit was shown to be safe and possibly protective against fatal infections, particularly in reducing infectious deaths. However, there was no effect of BCG vaccination on deaths due to prematurity and perinatal complications.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Maria A. Duarte C., Jeismar M. Carballo O., Yetsenia M. De Gouveia, Angie Garcia, Diana Ruiz, Teresa Gledhill, Eglys Gonzalez-Marcano, Ana F. Convit
Summary: ConvitVax is a personalized vaccine for breast cancer treatment, which has been shown to be safe and effective in preclinical studies on BALB/c mice.
SCIENTIFIC REPORTS
(2021)
Review
Microbiology
Esma Mouhoub, Pilar Domenech, Momar Ndao, Michael B. Reed
Summary: Live attenuated Bacillus Calmette-Guerin (BCG) vaccine is widely used for preventing tuberculosis, but has also shown protection against other pathogens. Recombinant BCG technology has been used to create vaccines that elicit immunity against bacterial, viral, and parasitic diseases. This review aims to provide an overview of rBCG-based vaccines targeting infectious diseases other than TB.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Veterinary Sciences
Saraswathi Subramanian, Sreenidhi Srinivasan, Kathiravan Ramaiyan Selvaraju, Priyadharshini Michael Vinoli, Suganya Selladurai, Boominathan Ramasamy, Karthik Kumaragurubaran, Douwe Bakker, Martin Vordermeier, Vivek Kapur, Dhinakar Raj Gopal
Summary: The BCG vaccine provides partial protection against bovine tuberculosis in cattle. A peptide-based defined antigen skin test (DST) has been developed to differentiate between BCG-vaccinated and bTB-infected animals. This study demonstrates that DST retains its diagnostic specificity even after revaccination with BCG.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Review
Microbiology
Kent J. Koster, Hilary L. Webb, Jeffrey D. Cirillo
Summary: BCG vaccination, widely used for protection against tuberculosis and providing non-specific protection against infectious respiratory diseases, has seen renewed interest in the context of the COVID-19 pandemic. Despite its benefits, the United States does not recommend BCG vaccination due to variable effectiveness against adult TB and other factors.
Article
Microbiology
Juan Wu, Zhidong Hu, Shui-Hua Lu, Xiao-Yong Fan
Summary: This study examined the ability of a DNA vaccine expressing a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against tuberculosis. The results showed that the DNA boost significantly amplified Th1-type cell-mediated immunity and reduced bacterial loads and histological damage in the lung.
FRONTIERS IN MICROBIOLOGY
(2022)
Review
Immunology
Junli Li, Lingjun Zhan, Chuan Qin
Summary: BCG vaccine, proven to be effective against tuberculosis, also shows non-specific protective effects against various diseases. The recent COVID-19 outbreak has brought BCG vaccine, a classic vaccine, back into the spotlight, prompting further research into its specific and non-specific protection mechanisms.
Article
Biology
Utpala Nanda Chowdhury, Md Omar Faruqe, Md Mehedy, Shamim Ahmad, M. Babul Islam, Watshara Shoombuatong, A. K. M. Azad, Mohammad Ali Moni
Summary: The study found that the BCG vaccine may have an impact on the severity and mortality of COVID-19, identifying genetic variations through analyzing shared DEGs and PPI network, and discovering potential therapeutic candidates. Further investigation into the genetic interactions between the BCG vaccine and SARS-CoV-2 could help combat the spread of COVID-19.
COMPUTERS IN BIOLOGY AND MEDICINE
(2021)
Article
Infectious Diseases
Peng Lu, Yu Zhang, Qiao Liu, Xianyan Ding, Wen Kong, Limei Zhu, Wei Lu
Summary: The study found that individuals with diabetes are at a higher risk of developing tuberculosis, especially when they are not overweight. Targeted screening should be considered based on these findings.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Saba Savul, Susan Duthie
Summary: This study reviewed the BCG vaccination records from 2019 to 2021 in Grampian, Scotland and found a high uptake rate, surpassing the key performance indicator target in Scotland and showing improvement compared to earlier rates. Strengthening electronic systems and raising awareness can further enhance BCG vaccination uptake.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Public, Environmental & Occupational Health
Fan Chen, Guo X. Chen, Jing Zhou, Yun Xue, Mei X. Wu
Summary: This study found that COVID-19 patients who received Bacille Calmette-Guerin vaccination showed lower severity of pneumonia and milder liver function deficiency during disease progression, as well as a lower death rate compared to unvaccinated individuals.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2021)